XORTX Announces Results of Annual and Special Meeting of Shareholders
Rhea-AI Summary
XORTX (NASDAQ: XRTX) announced results of its annual and special meeting held March 24, 2026. Approximately 2,407,148 common shares were represented, about 35% of outstanding shares. All matters presented were approved, including election of five directors, auditor appointment, reapproval of the stock option plan, and approval of a share consolidation.
Detailed voting results are available in the Report of Voting Results filed on the company’s SEDAR+ profile.
Positive
- None.
Negative
- None.
News Market Reaction – XRTX
In the Mar 27 session, XRTX gained 9.88%, reflecting a notable positive market reaction. Argus tracked a trough of -15.9% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. Trading volume was above average at 1.6x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 24 | Share consolidation approval | Neutral | -0.8% | Shareholders authorized up to 5‑for‑1 share consolidation to support Nasdaq listing. |
| Mar 18 | Director nominees, financing | Positive | +6.5% | Three substitute director nominees proposed as a condition of significant financing talks. |
| Mar 05 | Meeting materials mailed | Neutral | +7.8% | Filed and mailed meeting documents outlining votes on directors, auditor and consolidation. |
| Feb 04 | Acquisition timeline update | Positive | -17.7% | Extended deadline to close Vectus renal anti‑fibrotic program acquisition and granted options. |
| Dec 31 | Research & corporate update | Positive | +1.4% | Highlighted gout genetics research, board changes and completion of a US$1.1M financing. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news reactions mostly aligned with the underlying tone: governance and meeting process updates have seen modest positive or flat moves, while financing/acquisition-related updates have drawn the sharpest negative reaction.
Over the last six months, XRTX has focused on governance, financing flexibility and strategic assets. Multiple March 2026 releases detailed meeting materials, director nominations tied to a significant financing, and shareholder approval of a share consolidation to address Nasdaq bid-price requirements. Earlier, the company extended timelines to acquire a renal anti-fibrotic program and highlighted genomic research in gout alongside a prior US$1.1M financing. Today’s confirmation of annual and special meeting results fits this sequence of corporate and listing-standards housekeeping steps.
Key Terms
stock option plan financial
board of directors financial
auditors financial
SEDAR+ regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
CALGARY, Alberta, March 26, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce the results of its annual and special meeting of shareholders (the “Meeting”) held Tuesday, March 24, 2026.
A total of 2,407,148 common shares of the Company were represented at the Meeting, representing approximately
About XORTX Therapeutics Inc.
XORTX is a pharmaceutical company with three clinically advanced products in development: 1) our lead program XRx-026 program for the treatment of gout; 2) XRx-008 program for ADPKD; and 3) XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type 2 diabetic nephropathy. XORTX is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases. Additional information on XORTX is available at www.xortx.com.
For more information, please contact:
| Allen Davidoff, CEO | Nick Rigopulos, Director of Communications | |
| adavidoff@xortx.com | nick@alpineequityadv.com | |
| +1 403 455 7727 | +1 617 901 0785 |
Forward Looking Statements
This press release contains express or implied forward-looking statements pursuant to applicable securities laws. These forward-looking statements include, but are not limited to, the Company's beliefs, plans, goals, objectives, expectations, assumptions, estimates, intentions, future performance, other statements that are not historical facts and statements identified by words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or words of similar meaning. These forward-looking statements and their implications are based on the current expectations of the management of XORTX only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks, uncertainties, and other factors include, but are not limited to, regulatory approvals, such as the TSXV; the ability to complete the Consolidation; the success and timing of our preclinical studies and clinical trials; the performance of third-party manufacturers and contract research organizations; our plans to develop and commercialize our product candidates; our plans to advance research in other kidney disease applications; and, our ability to obtain and maintain intellectual property protection for our product candidates. Except as otherwise required by applicable law and stock exchange rules, XORTX undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting XORTX is contained under the heading “Risk Factors” in XORTX’s Annual Report on Form 20-F filed with the SEC, which is available on the SEC's website, www.sec.gov (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada, which are available on www.sedarplus.ca.
